NICE recommends Tecentriq and Avastin in advanced or unresectable HCC

12 November 2020

The UK National Institute of Health and Care Excellence (NICE) has issued a positive final appraisal document (FAD) for the use of Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for the treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

This recommendation comes less than two weeks after the European Medicines Agency approved the two Roche (ROG: SIX) drugs in this indication, which is the most common form of liver cancer.

"Tecentriq, in combination with Avastin, is the only cancer immunotherapy treatment, approved by NICE for this indication"Gemma Boni, head of liver cancer, Roche Products, said: “This news underlines our commitment to ensuring that people with liver cancer across England continue to get access to new treatments, even during this unprecedented time.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK